British drugmaker GSK said Friday that its experimental therapy for advanced or relapsed small-cell lung cancer showed positive results in a late-stage clinical trial, marking another milestone in the company's broader push into antibody-drug conjugates licensed from a Chinese biotech partner.
What the Trial Found
The drug, known as Ris-Rez, showed "statistically significant and clinically meaningful" improvements in overall survival compared with standard care, GSK said. Ris-Rez is an antibody-drug conjugate—a targeted medicine that pairs an antibody capable of identifying specific cancer cells with a potent drug designed to destroy them—that targets the B7-H3 protein found on the surface of cancer cells. According to the company, these are the first positive phase III overall survival data reported for any B7-H3-targeted antibody-drug conjugate, a notable distinction in a competitive area of oncology drug development. The results come from GSK's global phase III EMBOLD SCLC-301 trial, which evaluated Ris-Rez in patients with relapsed extensive-stage small-cell lung cancer; the company said additional pivotal data from the study are expected next year, which will be a key milestone in assessing the medicine's potential outside China.
Where the Drug Came From
Ris-Rez is licensed by GSK from China's Hansoh Pharma, which retains rights within China while GSK holds development and commercialization rights elsewhere. The drug is being studied for use across multiple tumor types beyond small-cell lung cancer, including prostate cancer, reflecting the broader ambitions GSK has for the B7-H3-targeting approach.
Part of a Broader Pipeline Bet
Friday's news adds to a string of positive updates for GSK's Hansoh-licensed oncology portfolio. The company said in April that another experimental targeted cancer therapy it has licensed from Hansoh, known as Mo-Rez (mocertatug rezetecan), has blockbuster potential. Mo-Rez is a separate antibody-drug conjugate that targets the B7-H4 antigen rather than B7-H3, and earlier this year GSK presented positive phase I data from its BEHOLD-1 trial evaluating the drug in platinum-resistant ovarian cancer and endometrial cancer. Based on that early efficacy and safety profile, GSK has advanced Mo-Rez into five separate pivotal phase III trials launched in 2026, spanning platinum-resistant and platinum-sensitive ovarian cancer, first-line maintenance settings, and mismatch-repair-proficient endometrial cancer.
Why This Matters for GSK's Oncology Strategy
Together, the Ris-Rez and Mo-Rez programs illustrate how GSK has leaned on licensing deals with Chinese biotech firms to build out its next-generation oncology pipeline around the antibody-drug conjugate class of medicines—a category that has drawn significant investment across the pharmaceutical industry in recent years for its ability to deliver cancer-killing drugs more precisely to tumor cells while sparing healthy tissue. While Friday's data reduces mechanism-level risk for the Ris-Rez program by demonstrating that targeting B7-H3 can meaningfully extend survival, it does not yet provide immediate revenue visibility; that will depend on the additional pivotal data expected next year and, ultimately, on regulatory review.
What's Next
Investors and oncologists alike will be watching for the follow-up data from the EMBOLD SCLC-301 trial next year, along with progress across GSK's five newly launched Mo-Rez phase III studies, as the company works to translate early and mid-stage promise from its Hansoh-licensed pipeline into approved therapies. Small-cell lung cancer remains a notoriously difficult cancer to treat, with historically poor survival outcomes once the disease relapses, making any therapy that meaningfully extends survival a significant development for patients and the broader oncology field.